Multifocality and multicentricity are not contraindications for sentinel lymph node biopsy in breast cancer surgery

Table 1 Summary of validation studies of SLNB in MF-MC breast tumors published in the Literature, 1999–2006

Author	year	Study	n. pts	Mapping technique	ID %	FN %	ACC %
Mertz³⁰	1999	Prospective	16	A*	98	0	100
Schrenk³¹	2001	Prospective	19	A^blue +/- A*	100	0	100
Kim¹¹	2002	Case reports	5	1ID* + T^blue	100	nv	nv
Fernandez³²	2002	Multicentric trial	53	T^+blue or ID^+blue or A*^+blue	98	0	100
Ozmen³³	2002	Prospective	21 MF	T^blue	85,7	33,3	77,8
Kumar³⁴	2003	Retrospective	59 (48 AD)	T^blue + 1–2ID*	93,5	0	100
Tousimis³⁵	2003	Retrospective	70	T*^+blue	95,9	8	96
Kumar³⁶	2004	Retrospective	10 (8 AD)	T* or A*^+blue	100	0	100
Goyal³⁷	2004	Multicentric trial	75 (AD or S)	T*^+blue	94,6	8,8	95,8
Knauer³⁸	2006	Multicentric trial	150 (125 AD)	ns (* or/+^blue)	ns	4,1	97,4
Current study	2006	Prospective	31	2ID* or A*	100	7,1	96,8

A = areolar injection of radioisotope (A*) or blue dye (A^blue)
ID = intradermal injection of radioisotope (ID*) or blue dye (ID^blue) over one (1ID) or two (2ID) neoplastic foci
T = peritumoral injection of radioisotope (T*) or blue dye (T^blue)
ns = non specified
AD = axillary dissection
S = lymph node sampling

ISSN: 1477-7819